Insider Transactions in Q1 2019 at Cvs Health Corp (CVS)
Insider Transaction List (Q1 2019)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2019
|
Fernando Aguirre Director |
BUY
Open market or private purchase
|
Direct |
1,900
+10.48%
|
$100,700
$53.59 P/Share
|
|
Mar 11
2019
|
C David Brown Ii Director |
BUY
Open market or private purchase
|
Direct |
10,000
+8.25%
|
$530,000
$53.18 P/Share
|
|
Mar 08
2019
|
David W Dorman Director |
BUY
Open market or private purchase
|
Direct |
9,600
+7.28%
|
$499,200
$52.71 P/Share
|
|
Mar 08
2019
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
2,000
+21.33%
|
$104,000
$52.8 P/Share
|
|
Mar 01
2019
|
Edward J Ludwig Director |
BUY
Open market or private purchase
|
Direct |
4,000
+42.65%
|
$232,000
$58.27 P/Share
|
|
Mar 01
2019
|
Fernando Aguirre Director |
BUY
Open market or private purchase
|
Direct |
3,410
+19.23%
|
$197,780
$58.29 P/Share
|
|
Mar 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,664
+16.28%
|
$74,880
$45.07 P/Share
|
|
Mar 01
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Open market or private sale
|
Direct |
1,664
-19.45%
|
$96,512
$58.14 P/Share
|
|
Feb 28
2019
|
Thomas M Moriarty EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,120
-15.98%
|
$348,840
$57.83 P/Share
|
|
Feb 28
2019
|
Thomas M Moriarty EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,869
+22.1%
|
$619,533
$57.83 P/Share
|
|
Feb 28
2019
|
Eva C Boratto EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,893
+4.13%
|
$107,901
$57.83 P/Share
|
|
Feb 28
2019
|
Eva C Boratto EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,101
-2.55%
|
$62,757
$57.83 P/Share
|
|
Feb 28
2019
|
Larry J Merlo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
27,731
-7.63%
|
$1,580,667
$57.83 P/Share
|
|
Feb 28
2019
|
Larry J Merlo Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,431
+8.42%
|
$1,905,567
$57.83 P/Share
|
|
Feb 28
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,323
+12.71%
|
$75,411
$57.83 P/Share
|
|
Feb 28
2019
|
James David Clark SVP, Cont & Chief Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
288
-3.26%
|
$16,416
$57.83 P/Share
|
|
Feb 28
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,183
+11.55%
|
$1,549,431
$57.83 P/Share
|
|
Feb 28
2019
|
Alan Lotvin EVP&President-PharmacyServices |
BUY
Grant, award, or other acquisition
|
Direct |
6,342
+29.52%
|
$361,494
$57.83 P/Share
|
|
Feb 28
2019
|
Alan Lotvin EVP&President-PharmacyServices |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-5.03%
|
$16,644
$57.83 P/Share
|
|
Feb 28
2019
|
Troyen A Brennan EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,114
-5.14%
|
$234,498
$57.83 P/Share
|
|
Feb 28
2019
|
Troyen A Brennan EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,477
+10.6%
|
$540,189
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
2,297
+11.45%
|
$130,929
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
BUY
Grant, award, or other acquisition
|
Direct |
1,268
+7.25%
|
$72,276
$57.83 P/Share
|
|
Feb 28
2019
|
Joshua Matthew Flum EVP, ENT STRATEGY & DIGITAL |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-6.21%
|
$56,430
$57.83 P/Share
|
|
Feb 28
2019
|
Kevin Hourican EVP & President, CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct |
9,467
+49.19%
|
$539,619
$57.83 P/Share
|
|
Feb 28
2019
|
Kevin Hourican EVP & President, CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct |
4,489
-93.52%
|
$255,873
$57.83 P/Share
|
|
Feb 28
2019
|
Lisa Bisaccia Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,015
-10.75%
|
$171,855
$57.83 P/Share
|
|
Feb 28
2019
|
Lisa Bisaccia Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,952
+19.87%
|
$396,264
$57.83 P/Share
|
|
Feb 19
2019
|
Karen S Lynch President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,617
-23.09%
|
$2,526,573
$69.88 P/Share
|
|
Feb 01
2019
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
166,368
-33.5%
|
$10,647,552
$64.51 P/Share
|
|
Feb 01
2019
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
166,368
+25.1%
|
$7,486,560
$45.07 P/Share
|
|
Feb 01
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
77,639
-69.69%
|
$4,968,896
$64.54 P/Share
|
|
Feb 01
2019
|
Jonathan C Roberts EVP & Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
77,639
+41.07%
|
$3,493,755
$45.07 P/Share
|
|
Jan 08
2019
|
Larry J Merlo Director |
SELL
Open market or private sale
|
Direct |
166,368
-33.5%
|
$11,479,392
$69.04 P/Share
|
|
Jan 08
2019
|
Larry J Merlo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
166,368
+25.1%
|
$7,486,560
$45.07 P/Share
|